Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study
United European Gastroenterology Journal · 2024-06 · 12 (5) · 543-551
DOI: 10.1002/ueg2.12492 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 28.02.2024. Verfasst von Mariangela Allocca und 34 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Piperidines, Ustekinumab, Colitis, Ulcerative, Pyrimidines. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Ustekinumab and tofacitinib have recently been approved for the management of moderate to severe ulcerative colitis (UC). However, there is no evidence on how they should be positioned in the therapeutic algorithm. The aim of this study was to compare tofacitinib and ustekinumab as third‐line therapies in UC patients in whom anti‐TNF and vedolizumab had failed.
Methods
This was a multicenter retrospective observational study. The primary outcome was disease progression, defined as the need for steroids, therapy escalation, UC‐related hospitalization and/or surgery. Secondary outcomes were clinical remission, normalization of C‐reactive protein, endoscopic remission, treatment withdrawal, and adverse events.
Results
One‐hundred seventeen UC patients were included in the study and followed for a median time of 11.6 months (q 1 –q 3, 5.5–18.7). Overall, 65% of patients were treated with tofacitinib and 35% with ustekinumab. In the entire study cohort, 63 patients (54%) had disease progression during the follow‐up period. Treatment with ustekinumab predicted increased risk of disease progression compared to treatment with tofacitinib in Cox regression analysis (HR: 1.93 [95% CI: 1.06–3.50] p = 0.030). Twenty‐eight (68%) patients in the ustekinumab group and 35 (46%) in the tofacitinib group had disease progression over the follow‐up period (log‐rank test, p < 0.054). No significant differences were observed for the secondary outcomes. Six and 22 adverse events occurred in the ustekinumab and tofacitinib groups, respectively (15% vs. 31%, p = 0.11).
Conclusions
Tofacitinib was more efficacious in reducing disease progression than ustekinumab in this cohort of refractory UC patients. However, prospective head‐to‐head clinical trials are needed as to confirm these data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
- Department of Surgery, Oncology and Gastroenterology, Division of Gastroenterology, University of Padua, Padua, Italy.
- Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digesti…
- Gastroenterology, Sheba Medical Center, Tel Hashomer, Tel-Aviv University, Tel-Aviv, Israel.
- Gastroenterology, General Hospital of Athens "G. Gennimatas", Athens, Greece.
- Gastroenterology, 'Evangelismos-Polykliniki' GHA, Athens, Greece.
ORCID-Profile: Mariangela Allocca, María Chaparro, Daniele Noviello, Catarina Neto do Nascimento, María José García, Ferdinando D'Amico, Pierre Ellul, Laurent Peyrin-Biroulet, Joana Torres, Uri Kopylov, Javier P Gisbert, Silvio Danese, Fernando Magro, Gionata Fiorino
Zitieren
APA
Allocca, M., Catalano, G., Savarino, E. V., Chaparro, M., Levartovsky, A., Michalopoulos, G., Viazis, N., Fousekis, F. S., Psistakis, A., Noviello, D., Nascimento, C. N. D., Caron, B., Kitsou, V., Bamias, G., García, M. J., Zacharopoulou, E., Foteinogiannopoulou, K., D'Amico, F., Koutroubakis, I., …, & Fiorino, G. (2024). Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study. United European Gastroenterology Journal, 12(5), 543-551. https://doi.org/10.1002/ueg2.12492
Vancouver
Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, et al. Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study. United European Gastroenterology Journal. 2024;12(5):543-551. doi:10.1002/ueg2.12492
BibTeX
@article{Allocca2024,
author = {Allocca, Mariangela and Catalano, Gaia and Savarino, Edoardo V and Chaparro, María and Levartovsky, Asaf and Michalopoulos, George and Viazis, Nikos and Fousekis, Fotis S and Psistakis, Andreas and Noviello, Daniele and Nascimento, Catarina Neto do and Caron, Benedicte and Kitsou, Vassiliki and Bamias, Giorgos and García, María José and Zacharopoulou, Eirini and Foteinogiannopoulou, Kalliopi and D'Amico, Ferdinando and Koutroubakis, Ioannis and Ellul, Pierre and Tzouvala, Maria and Peyrin-Biroulet, Laurent and Torres, Joana and Caprioli, Flavio and Karmiris, Konstantinos and Theodoropoulou, Angeliki and Katsanos, Konstantinos H and Christodoulou, Dimitrios K and Mantzaris, Gerassimos J and Kopylov, Uri and Gisbert, Javier P and Danese, Silvio and Magro, Fernando and Carla, Fornari and Fiorino, Gionata},
title = {Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study},
journal = {United European Gastroenterology Journal},
year = {2024},
volume = {12},
number = {5},
pages = {543--551},
doi = {10.1002/ueg2.12492}
}
EUVIMED